Ernesto Wasserman

2.4k total citations
35 papers, 1.2k citations indexed

About

Ernesto Wasserman is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ernesto Wasserman has authored 35 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 13 papers in Molecular Biology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ernesto Wasserman's work include HER2/EGFR in Cancer Research (10 papers), Lung Cancer Treatments and Mutations (7 papers) and Colorectal Cancer Treatments and Studies (6 papers). Ernesto Wasserman is often cited by papers focused on HER2/EGFR in Cancer Research (10 papers), Lung Cancer Treatments and Mutations (7 papers) and Colorectal Cancer Treatments and Studies (6 papers). Ernesto Wasserman collaborates with scholars based in United States, France and Spain. Ernesto Wasserman's co-authors include Esteban Cvitkovic, William Sutherland, François Goldwasser, François Lokiec, Mitesh J. Borad, Joseph J. Stephenson, Susan B. Brown, Stephen P. Anthony, Cristian Fernández and Gayle Jameson and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Ernesto Wasserman

35 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ernesto Wasserman United States	17	812	418	377	358	141	35	1.2k
Chiara Pierantoni Italy	16	809 1.0×	340 0.8×	245 0.6×	366 1.0×	155 1.1×	40	1.3k
Véronique D’Hondt France	21	781 1.0×	298 0.7×	241 0.6×	335 0.9×	144 1.0×	83	1.3k
Tae-You Kim South Korea	24	689 0.8×	678 1.6×	277 0.7×	420 1.2×	168 1.2×	48	1.5k
V. Damiano Italy	15	796 1.0×	502 1.2×	181 0.5×	568 1.6×	105 0.7×	34	1.3k
Diana L. Hanna United States	17	600 0.7×	238 0.6×	258 0.7×	250 0.7×	164 1.2×	75	1.0k
Edgardo S. Santos United States	21	576 0.7×	384 0.9×	230 0.6×	524 1.5×	88 0.6×	101	1.2k
Débora De Melo Gagliato Brazil	14	953 1.2×	426 1.0×	501 1.3×	528 1.5×	170 1.2×	36	1.5k
Saeed Sadeghi United States	17	1.1k 1.4×	366 0.9×	444 1.2×	513 1.4×	289 2.0×	42	1.7k
Gregory Friberg United States	18	722 0.9×	504 1.2×	269 0.7×	318 0.9×	83 0.6×	35	1.2k
Linnea Chap United States	13	1.0k 1.3×	662 1.6×	417 1.1×	367 1.0×	46 0.3×	28	1.7k

Countries citing papers authored by Ernesto Wasserman

Since Specialization

Citations

This map shows the geographic impact of Ernesto Wasserman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ernesto Wasserman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ernesto Wasserman more than expected).

Fields of papers citing papers by Ernesto Wasserman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ernesto Wasserman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ernesto Wasserman. The network helps show where Ernesto Wasserman may publish in the future.

Co-authorship network of co-authors of Ernesto Wasserman

This figure shows the co-authorship network connecting the top 25 collaborators of Ernesto Wasserman. A scholar is included among the top collaborators of Ernesto Wasserman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ernesto Wasserman. Ernesto Wasserman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schram, Alison M., Teresa Macarulla, James M. Cleary, et al.. (2023). 1618P Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC). Annals of Oncology. 34. S895–S896. 11 indexed citations

Fontana, Elisa, Gonzalo Torga, Susan Cleator, et al.. (2022). Sustained Tumor Regression With Zenocutuzumab, a Bispecific Antibody Targeting Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 Signaling, in NRG1 Fusion–Positive, Estrogen Receptor–Positive Breast Cancer After Progression on a Cyclin-Dependent Kinase 4/6 Inhibitor. JCO Precision Oncology. 6(6). e2100446–e2100446. 5 indexed citations

Schram, Alison M., Kōichi Goto, Dong‐Wan Kim, et al.. (2022). Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers.. Journal of Clinical Oncology. 40(16_suppl). 105–105. 54 indexed citations

Argilés, Guillem, Christiane Jungels, Rocio García‐Carbonero, et al.. (2021). Phase I dose-escalation study of MCLA-158, a first-in-class bispecific antibody targeting EGFR and LGR5, in metastatic colorectal cancer (CRC).. Journal of Clinical Oncology. 39(3_suppl). 62–62. 5 indexed citations

Bol, Kees, Robert P. Doornbos, Anastasia Murat, et al.. (2020). Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors. Clinical Pharmacokinetics. 59(7). 875–884. 17 indexed citations

Schram, Alison M., Alexander Drilon, Teresa Macarulla, et al.. (2020). A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors.. Journal of Clinical Oncology. 38(15_suppl). TPS3654–TPS3654. 17 indexed citations

Schram, Alison M., Eileen M. O’Reilly, Romel Somwar, et al.. (2019). Abstract PR02: Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers. Molecular Cancer Therapeutics. 18(12_Supplement). PR02–PR02. 24 indexed citations

Agarwal, Neeraj, Jean-Pascal Machiels, Cristina Suárez, et al.. (2016). Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer. The Oncologist. 21(5). 535–536i. 48 indexed citations

Dummer, Reinhard, Dirk Schadendorf, Paolo A. Ascierto, et al.. (2016). Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma.. Journal of Clinical Oncology. 34(15_suppl). 9500–9500. 24 indexed citations

10.

Long, Georgina V., Reinhard Dummer, Keith T. Flaherty, et al.. (2015). Abstract B16: NEMO: A phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with advanced NRAS-mutant melanoma who are untreated or have progressed on or after immunotherapy. Cancer Research. 75(14_Supplement). B16–B16. 1 indexed citations

11.

Ribas, Antoni, Luis H. Camacho, Sun Min Lee, et al.. (2010). Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma. Journal of Translational Medicine. 8(1). 89–89. 29 indexed citations

12.

Sharma, Sunil, Raoul Tibes, Ernesto Wasserman, et al.. (2009). Abstract C131: CBP501 (CBP), a novel cell cycle dysregulator, in combination with cisplatin (CDDP) and pemetrexed (PM) - pharmacokinetics (PK) in two phase I/II studies. Molecular Cancer Therapeutics. 8(12_Supplement). C131–C131. 1 indexed citations

13.

Sharma, Sunil, Raoul Tibes, Bruno R. Bastos, et al.. (2009). Abstract B47: CBP501, a novel cell cycle dysregulator, in combination with cisplatin (CDDP) and pemetrexed (PM) - results of two phase I/II studies. Molecular Cancer Therapeutics. 8(12_Supplement). B47–B47. 1 indexed citations

14.

Wong, Bert Y.S., Geoffrey I. Shapiro, Michael Gordon, et al.. (2008). Phase I studies of CBP501, a novel G2 checkpoint abrogator, alone and combined with cisplatin (CDDP) in advanced solid tumor patients (pts). Journal of Clinical Oncology. 26(15_suppl). 2528–2528. 1 indexed citations

15.

Chacón, Matías, Ernesto Korbenfeld, Santiago Bella, et al.. (2006). Irinotecan, Oxaliplatin Plus Bolus 5-Fluorouracil and Low Dose Folinic Acid Every 2 Weeks. American Journal of Clinical Oncology. 29(1). 45–51. 6 indexed citations

16.

Germann, N., Marine Gross‐Goupil, Ernesto Wasserman, et al.. (2002). The chemotherapy of metastatic gastric adenocarcinomas with hypersecretion of α-fetoprotein or β-human chorionic gonadotrophin: report of two cases. Annals of Oncology. 13(4). 632–636. 9 indexed citations

17.

Wasserman, Ernesto, William Sutherland, & Esteban Cvitkovic. (2001). Irinotecan plus Oxaliplatin: a Promising Combination for Advanced Colorectal Cancer. Clinical Colorectal Cancer. 1(3). 149–153. 22 indexed citations

18.

Goldwasser, François, Marine Gross‐Goupil, Jean‐Marie Tigaud, et al.. (2000). Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: A phase I study in advanced gastrointestinal cancer patients. Annals of Oncology. 11(11). 1463–1470. 46 indexed citations

19.

Cvitkovic, Esteban & Ernesto Wasserman. (1997). Role of vindesine as neoadjuvant chemotherapy for non-small cell lung and head and neck cancers. Anti-Cancer Drugs. 8(8). 734–745. 2 indexed citations

20.

Wasserman, Ernesto, Anne Myara, François Lokiec, et al.. (1997). Severe CPT-11 toxicity in patients with Gilbert's syndrome: Two case reports. Annals of Oncology. 8(10). 1049–1051. 146 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact